Slide 1: Investor presentation: Connectivity that liberates healthcare
Connectivity that liberates healthcare Investor presentation Results for the six months ending 30 November 2024 (H1 2025) Bleepa is a product by Feedback Medical | Feedback plc is a company registered in England and Wales Reg No: 00598696 | Reg Office: 201 Temple Chambers 3-7 Temple Avenue, London,
Slide 2: Disclaimer
Disclaimer The information contained in this confidential document (the “Presentation”) and any information disclosed in any oral presentation thereof has been prepared by Feedback plc (the “Company”). It has not been fully verified and is subject to material updating, revision and further amendment
Slide 3: Operational highlights
FEEDBACK PLC INVESTOR PRESENTATION HALF YEAR RESULTS 2025 Operational highlights • Awarded £495k contract by QVH as successful bidder to provide digital infrastructure Routes to market • Awarded further funding to extend the delivery of its CDC pathway pilot at the NCA site in Oldham • New UK govern
Slide 4: Financial highlights
FEEDBACK PLC INVESTOR PRESENTATION HALF YEAR RESULTS 2025 Financial highlights (all figures in £million) Revenue: £0.45m (H1 2024: £0.44m), up 3% due to inflationary price Revenue & Sales EBITDA loss increases on existing client contracts and pilot at QVH successfully converting to full contract at
Slide 5: Post-period highlights
FEEDBACK PLC INVESTOR PRESENTATION HALF YEAR RESULTS 2025 Post-period highlights • Two revenue-generating projects operationalised in India - pilot with a large Asian hospital group and Tuberculosis Routes to market (“TB”) screening programme with HEAL Foundation • Continued alignment with governmen
Slide 6: Investment case
FEEDBACK PLC INVESTOR PRESENTATION Investment case Routes to market UK Government and NHSE alignment • UK: NHS cross-provider care and NHS Trusts and private sector • Bleepa perfectly aligned to the government’s biggest health (TAM of £339m) priority (elective care waiting lists) with established us
Slide 7: Growth drivers
Growth drivers (1) New administration, (2) Partners as a (3) Funding mechanism (4) Diversifying new NHS platform for growth outside the NHS Bleepa is a product by Feedback Medical | Feedback Medical is a company registered in England and Wales Reg No: 04025026 | Reg Office: 201 Temple Chambers 3-7 T
Slide 8: Policy drivers in the NHS
FEEDBACK PLC INVESTOR PRESENTATION HALF YEAR RESULTS 2025 (1) New administration, new NHS (2) Partners as a platform for growth (3) Funding mechanism (4) Diversifying outside the NHS Policy drivers in the NHS New administration, New NHS Lord Darzi report on NHS Tony Blair Institute report on APPG fo
Slide 9: Collaboration with a UK primary care record provider (1/2)
FEEDBACK PLC INVESTOR PRESENTATION HALF YEAR RESULTS 2025 (1) New administration, new NHS (2) Partners as a platform for growth (3) Funding mechanism (4) Diversifying outside the NHS Collaboration with a UK primary care record provider (1/2) Wes Streeting has called for a 'Neighbourhood Health Servi
Slide 10: Collaboration with a UK primary care record provider (2/2)
FEEDBACK PLC INVESTOR PRESENTATION HALF YEAR RESULTS 2025 (1) New administration, new NHS (2) Partners as a platform for growth (3) Funding mechanism (4) Diversifying outside the NHS Collaboration with a UK primary care record provider (2/2) What Feedback brings: • Scalable pathway technology with b
Slide 11: Changing care models – Bleepa as a DEAG tool (1/2)
FEEDBACK PLC INVESTOR PRESENTATION HALF YEAR RESULTS 2025 (1) New administration, new NHS (2) Partners as a platform for growth (3) Funding mechanism (4) Diversifying outside the NHS Changing care models – Bleepa® as a DEAG tool (1/2) % re-referred to different specialty Today’s model: GP appt. Init
Slide 12: Changing care models – Bleepa as a DEAG tool (2/2)
FEEDBACK PLC INVESTOR PRESENTATION HALF YEAR RESULTS 2025 (1) New administration, new NHS (2) Partners as a platform for growth (3) Funding mechanism (4) Diversifying outside the NHS Changing care models – Bleepa® as a DEAG tool (2/2) Evidence of benefit/justification for NHS customers • Bleepa® res
Slide 13: Diversifying outside of the NHS
FEEDBACK PLC INVESTOR PRESENTATION HALF YEAR RESULTS 2025 (1) New administration, new NHS (2) Partners as a platform for growth (3) Funding mechanism (4) Diversifying outside the NHS Diversifying outside of the NHS • Subsidiary established, Rohit Singh, • Collaboration with Vertex In MD for India, l
Slide 14: Product overview
Product overview Bleepa is a product by Feedback Medical | Feedback Medical is a company registered in England and Wales Reg No: 04025026 | Reg Office: 201 Temple Chambers 3-7 Temple Avenue, London, EC4Y 0DT 14
Slide 15: Bleepa - clinician facing app
BLEEPA® INVESTOR PRESENTATION Bleepa® - clinician facing app Key features • Common view of a patient’s data, securely accessible from any location with an internet connection, bridging the gap between care settings and enabling seamless clinical pathway delivery. • Asynchronous collaboration environ
Slide 16: CareLocker - patient-facing app
CARELOCKER® INVESTOR PRESENTATION CareLocker® - patient-facing app Key features • Provides secure, easy-to-use management of patient’s imaging from the convenience of their own mobile. • Can be ‘white labelled’ with the branding of the purchaser or integrated within other health and lifestyle apps f
Slide 17: Regulatory accreditation
FEEDBACK MEDICAL INVESTOR PRESENTATION Regulatory accreditation • UKCA certified • ISO 13485 certified • ISO 27001 certified • Cyber Essentials Plus certified • DCB 0129: clinical risk management certified • Digital Technology Assessment Criteria (DTAC) certified 17
Slide 18: Acute trust customer impact – clinical communication
BLEEPA® INVESTOR PRESENTATION Acute trust customer impact – clinical communication Independent evaluation report of 10,000 inpatient referrals at NCA identified: • shorter average referral times • time savings for staff • shorter length of stay for patients • savings to the system from both a trust
Slide 19: ICB impact – CDC breathlessness pathway
BLEEPA® INVESTOR PRESENTATION ICB impact – CDC breathlessness pathway Queen Victoria Hospital (QVH) in Sussex set up a pilot in 2021 to redesign and implement an end-to-end breathlessness pathway. Bleepa was embedded as the technology enabler to provide the digitally integrated, asynchronous symptom
Slide 20: Outlook
FEEDBACK PLC INVESTOR PRESENTATION HALF YEAR RESULTS 2025 Outlook 1 Growing national and regional recognition of the need for our CDC solution 2 Key focus on cross-provider care delivery in the UK with higher contract values and margins Key focus on developing commercial partnerships to accelerate g
Slide 21: Appendices
Appendices Bleepa is a product by Feedback Medical | Feedback Medical is a company registered in England and Wales Reg No: 04025026 | Reg Office: 201 Temple Chambers 3-7 Temple Avenue, London, EC4Y 0DT 21
Slide 22: Feedback plc Board
FEEDBACK PLC INVESTOR PRESENTATION Feedback plc Board Prof Rory Shaw, Non-executive Dr Thomas Oakley, Chief Executive Chairman: Ex senior NHS executive, Officer: Qualified radiologist with Medical Director of Healthcare UK, Dept significant clinical and academic of International Trade, and consultan
Slide 23: Feedback Medical leadership team
FEEDBACK MEDICAL INVESTOR PRESENTATION Feedback Medical leadership team Dr Thomas Oakley, Chief Anesh Patel, Chief Financial Mike Hayball, Chief Technology Executive Officer: Qualified Officer: Chartered accountant with Officer: Medical imaging scientist radiologist with significant clinical signifi
Slide 24: Company history
FEEDBACK PLC INVESTOR PRESENTATION HALF YEAR RESULTS 2025 Company history • 12-month contract with QVH/Sussex ICS and pilot with Oldham CDC for CDC pathway programme 2024 • Pilot agreement with Medical Imaging Partnership for multiple clinical pathways • TB screening partnership in India and IHW Gol
Slide 25: ~£10bn annual TAM estimated in core target markets
FEEDBACK PLC INVESTOR PRESENTATION HALF YEAR RESULTS 2025 ~£10bn annual TAM estimated in core target markets Company estimated total addressable market – annual 1 2 3 4 5 6 7 NHS Private NHS NHS Private National TB ABDM(2) – Community hospitals TOTAL Trusts CDCs / ICS’ hospitals (UK) screening healt
Slide 26: H1 2025 – Consolidated income statement
FEEDBACK PLC INVESTOR PRESENTATION HALF YEAR RESULTS 2025 H1 2025 – Consolidated income statement H1 2025 H1 2024 FY 2024 £000 £000 £000 Revenue 449 437 1,181,544 Cost of sales (49) (36) (79,129) Gross profit 400 401 1,102,415 Other operating expenses (2,389) (2,536) (4,792,548) Operating loss (1,98
Slide 27: H1 2025 – Consolidated balance sheet
FEEDBACK PLC INVESTOR PRESENTATION HALF YEAR RESULTS 2025 H1 2025 – Consolidated balance sheet H1 2025 H1 2024 FY 2024 £000 £000 £000 Property, plant and equipment 8 14 13 Intangible assets 3,956 3,911 4,068 Total non-current assets 3,964 3,925 4,081 Trade and other receivables 100 435 82 Called up
Slide 28: H1 2025 – Consolidated cashflow statement
FEEDBACK PLC INVESTOR PRESENTATION HALF YEAR RESULTS 2025 H1 2025 – Consolidated cashflow statement H1 2025 H1 2024 FY 2024 £000 £000 £000 Cash flows from operating activities Loss before tax (1,951) (2,088) (3,597) Adjustments for: Net finance income (38) (47) (93) Depreciation and amortisation 554
Slide 29: Get in touch today to find out how Feedback plc can work for you
Get in touch today to find out how Feedback plc can work for you: sales@fbkmed.com | feedbackmedical.com 29